In 2019 NICE is due to commence the review of this guidance, to register as a stakeholder please contact us at email@example.com
NICE has developed medical technology guidance on the UroLift system.
NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ recommendations are based on the claimed advantages of introducing the specific technology compared with current management of the condition. This ‘case’ is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.
NICE has said that the UroLift system relieves lower urinary tract symptoms while avoiding the risk to sexual function associated with surgical options. Using the system reduces the length of a person’s stay in hospital. It can also be used in a day surgery unit.
The UroLift system should be considered as an alternative to current surgical procedures for men aged 50 years and older with lower urinary tract symptoms of benign prostatic hyperplasia, who have a prostate of less than 100 ml without an obstructing middle lobe.
NHS England and Monitor have published information on payments for “the insertion of prostatic urethral lift implants” in England. This can be found in the 2016/17 national prices and national tariff enquiry log on the NHS National Tariff Payment System 2016/17 government webpages (FAQs).
This states “where procedures are undertaken in 2016/17 which involve the insertion of prostatic urethral lift implants, we would encourage providers and commissioners to agree a local variation to the national price which better reflects the costs involved.”
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.